p21-activated kinase 1 (PAK1) is a serine/threonine kinase that is overexpressed in colorectal cancer. PAK1 is a target of mesalamine [5-aminosylicylic acid (5-ASA)], a common drug for the treatment of ulcerative colitis with prospective chemopreventive properties. Here, we investigated whether PAK1 deletion impedes tumorigenesis in murine intestinal cancer models. Ten-week-old APCmin or APCmin/PAK1−/− mice were monitored for 8 weeks, euthanized, and assessed for tumor number and size. Six- to 8-week-old PAK1−/− and wild-type (WT) mice received one 10 mg/kg intraperitoneal injection of azoxymethane (AOM) and four cycles of 1.7% dextran sodium sulfate (DSS) for 4 days followed by 14 days of regular water. Mice also received 5-ASA via diet. Tumor incidence and size was assessed via colonoscopy and pathology. Molecular targets of PAK1 and 5-ASA were evaluated via immunohistochemistry (IHC) in both models. PAK1 deletion reduced tumor multiplicity and tumor burden but did not alter average tumor size in APCmin mice. IHC revealed that PAK1 deletion reduced p-AKT, β-catenin, and c-Myc expression in APCmin adenomas. Colonoscopy and pathologic analysis revealed that PAK1 deletion reduced tumor multiplicity without affecting tumor size in AOM/DSS-treated mice. 5-ASA treatment and PAK1 deletion impeded tumor multiplicity and dysplastic lesions in AOM/DSS mice. IHC further revealed that 5-ASA blocked β-catenin signaling via inhibition of PAK1/p-AKT. These data indicate that PAK1 contributes to initiation of intestinal carcinogenesis. Cancer Prev Res; 8(11); 1093–101. ©2015 AACR.

Inflammatory bowel disease (IBD), such as ulcerative colitis, increases the risk of developing colitis-associated cancer (CAC; ref. 1). Epidemiologic evidence suggests that treatment of ulcerative colitis with mesalamine (5-ASA; 5-aminosalicylic acid) reduces the risk of developing CAC (2). Mechanistically, 5-ASA activates the nuclear receptor PPARγ (3) and reduces oxidative stress through inhibition of PI3K activity (4, 5). 5-ASA not only induces S-phase arrest and blocks cell proliferation (6) but also reduces the activation of AKT-β-catenin (7) and NF-κB signaling (8). In addition, we recently reported that p21-activated kinase 1 (PAK1) is a 5-ASA target, and its inhibition by 5-ASA improved intestinal barrier function by increasing membranous E-cadherin and β-catenin (9, 10).

PAK1 is a serine/threonine kinase effector of the small Rho GTPases Rac1/Cdc42 with both kinase and scaffolding activities (11). Accumulating evidence suggests that PAK1 signaling actively participates in gut homeostasis (12). Within intestinal crypts, PAK1 facilitates cell proliferation through sustainment of Wnt/β-catenin signaling (13, 14). PAK1 also regulates cytoskeletal rearrangements as well as cell survival pathways, such as NF-κB, which may be implicated in cell shedding along the villus axis in response to inflammatory cytokines or bacterial effector proteins (15, 16).

We recently found that PAK1 is overexpressed in IBD and CAC and demonstrated that PAK1 overexpression in colonic epithelial cells promotes proliferation and survival via Wnt/β-catenin and AKT/mTOR pathways (17, 18). Previous reports established that PAK1 expression increases with colorectal cancer progression (19) and have shown that knockdown of PAK1 within xenograft models reduces tumor size (20). However, it is unclear whether PAK1 deletion interferes with intestinal tumorigenesis.

Here, we investigated (i) the role of PAK1 upon loss of APC using APCmin/PAK1−/− mice, (ii) the role of PAK1 in inflammation-driven colon carcinogenesis using a PAK1−/− azoxymethane (AOM)/dextran sodium sulfate (DSS) model, and (iii) modulation of PAK1 signaling by 5-ASA.

Animal experiments

C57BL/6 PAK1−/− were obtained from the Mutant Mouse Regional Resource Center-University of North Carolina and bred with C57BL/6 APCmin mice to generate APCmin/PAK1−/− mice. All mice were genotyped to confirm PAK1 knockout and APC heterozygote status as previously described (21, 22). Mice were housed at the Institute of Biomedical Research (Medical University Vienna, Vienna, Austria) and kept under 12-hour light/dark cycles. Chow and water were available ad libitum, and the animals were weighed weekly. All experiments were performed in accordance with the Austrian and European law, defined by the Good Scientific Practice guidelines of the Medical University Vienna (animal ethics approval number: BMWFW-66.009/0268-WF/V/3b/2014 and BMWF-66.009/0294-11/3b/2012). Ten-week-old male and female APCmin (n = 10) and APCmin/PAK1−/− (n = 18) were weighed weekly for 8 weeks and then euthanized by cervical dislocation. Intestines were excised, flushed with PBS, and Swiss roles were fixed and paraffin embedded as described previously (21). Tumor multiplicity and burden were analyzed microscopically on an Olympus BX51 microscope using Cellsens dimension life science imaging software (Olympus). Tumor burden was calculated by drawing a polygon around the tumor and recorded in (mm2).

Six- to eight-week-old male and female C57BL/6 PAK1−/− (n = 48) or C57BL/6 wild-type (WT; n = 54) mice were randomly separated into two groups each, which received either a control or 5-ASA supplemented diet (500 mg/kg chow) starting together with azoxymethane treatment after a 2-week adaption phase on regular chow. All mice received one intraperitoneal injection of 10 mg/kg AOM and four intermittent cycles of 1.7% DSS in drinking water for 4 days followed by 14 days of regular water. Before euthanasia, both tumor incidence and size was assessed via colonoscopy and scored into small (<25%), medium (25%–50%), or large tumors (>50% of circumference). The bowel preparation was carried out as follows: mice were fasted for 24 hours, receiving a rehydration solution (13.5 g glucose, 2.9 g trisodium citrate dihydrate, 2.6 g NaCl, 1.5 g KCl in 1 L) supplied with PEG (34.5 g/L PEG 35000) to clean the large bowel. After anesthesia with an intraperitoneal injection of ketamine and xylazine, the colonoscope (Karl Storz) connected to an airpump (Eheim) was inserted and the colon inflated. Independent of the colonoscopy data, tumors were counted by a pathologist who was blinded to the group assignment and classified as dysplastic lesions, carcinoma in situ, or invasive carcinoma microscopically. Colonic inflammation was evaluated by two separate investigators as previously described (23, 24). Briefly, inflammation was scored using 10 separate high-power (40×) fields of view on a scale from (0–4), grade 0, normal colonic mucosa; grade 1, slightly inflamed lamina propria and mild shortening of crypts; grade 2, moderate inflammation of the lamina propria and two thirds loss of crypts; grade 3, sever inflammation of lamina propria with intact surface epithelium and complete loss of crypts; and grade 4, severe inflammation of lamina propria and complete loss of the crypts and surface epithelium.

Immunohistochemical analysis

Immunohistochemistry (IHC) was performed on paraffin-embedded sections from mouse intestinal tissue as described previously (9). Sections were dried, dewaxed, and rehydrated followed by blocking of endogenous peroxidase using 15% H2O2 in methanol for 10 minutes. Subsequent antigen retrieval was accomplished by boiling the sections in 10 mmol/L citrate buffer (pH 6). After blocking, the primary antibody was added in for overnight at 4°C in a humidified chamber (for a complete list of primary antibodies, see Supplementary Table S1). The biotinylated secondary antibody was applied for 30 minutes at room temperature. The avidin–biotin–HRP complex (Vectastain) was added (30 minutes), and 3,3′-diaminobenzidine (DAB; Fluka) was used to visualize the staining. Nuclear counterstaining was achieved with hematoxylin. Images were recorded on an Olympus BX51 microscope.

Immunoreactivity score

An immunoreactivity score (IRS) was generated by two blinded investigators (K. Dammann, F. Harpain) as previously described (17). The intensity of staining included a score from 0 to 3, 0 (no staining), 1 (low), 2 (medium), and 3 (high). The percentage of positively stained epithelial cells was evaluated on a scale from 0 to 4, 0 (<1%), 1 (1%–10%), 2 (10%–50%), 3 (51%–80%), and 4 (> 80%) in four separate fields of view. The mean intensity and percentage of positively stained epithelial cells was multiplied to generate the IRS, and the highest score attainable was 12. Data represent the mean of the 2 scorer's findings.

Statistical analysis

Statistical analysis was performed using SPSS (version 21.0). Metric outcome variables were compared using univariate ANOVA and least significant difference (LSD) post hoc tests. P < 0.05 was considered significant (*, P < 0.05; **, P < 0.01; ***, P < 0.001). All data are expressed as mean ± SD unless otherwise stated.

The effect of PAK1 deletion on tumorigenesis in APCmin mice

Intestinal tumorigenesis following loss of APC can be recapitulated using the APCmin mouse model. We previously demonstrated that PAK1 is overexpressed in tumors of APCmin mice and that 5-ASA reduced both PAK1 overexpression and small bowel tumor multiplicity in these mice (10). However, it was unclear whether inhibition of PAK1 by 5-ASA was required to carry out the effect of 5-ASA on reducing tumorigenesis. Here, we established APCmin/PAK1−/− mice to investigate the role of PAK1 on tumorigenesis upon loss of APC. Ten-week-old APCmin and APCmin/PAK1−/− mice were housed for 8 weeks (Fig. 1A) and then sacrificed to analyze tumor multiplicity in the small bowel. PAK1 deletion reduced both small bowel tumor number (Fig. 1B), and tumor burden (Fig. 1C). However, average tumor size was not altered in APCmin/PAK1−/− mice (Fig. 1D). These data indicated that following loss of APC, PAK1 deletion impedes tumor initiation but not tumor growth.

Figure 1.

A–D, effect of PAK1 deletion in APCmin mice. A, weight curves of APCmin (n = 10) and APCmin/PAK1−/− (n = 18) mice over the course of 8 weeks. Mice were 10 weeks old at the start of the experiment and lived a total of 18 weeks. B, microscopic tumor analysis of tumors in the small bowel. PAK1 deletion reduced small bowel tumors in APCmin mice. C, PAK1 deletion significantly reduced total tumor burden but did not affect (D) average tumor size. Tumor data are APCmin (n = 10) and APCmin/PAK1−/− mice (n = 18); independent sample t test. *, P < 0.05.

Figure 1.

A–D, effect of PAK1 deletion in APCmin mice. A, weight curves of APCmin (n = 10) and APCmin/PAK1−/− (n = 18) mice over the course of 8 weeks. Mice were 10 weeks old at the start of the experiment and lived a total of 18 weeks. B, microscopic tumor analysis of tumors in the small bowel. PAK1 deletion reduced small bowel tumors in APCmin mice. C, PAK1 deletion significantly reduced total tumor burden but did not affect (D) average tumor size. Tumor data are APCmin (n = 10) and APCmin/PAK1−/− mice (n = 18); independent sample t test. *, P < 0.05.

Close modal

PAK1 deletion impairs Wnt signaling in APCmin mice

Wnt/β-catenin signaling is a key regulator of crypt proliferation, and its aberrant activation upon loss of APC drives colorectal tumorigenesis (25). PAK1 phosphorylation of β-catenin at Ser-675 increases both β-catenin stability and transcriptional activation (13). IHC of β-catenin in untreated WT and PAK1−/− mice, which were WT for APC, revealed that β-catenin expression was prominently reduced throughout the crypts in PAK1−/− mice, in both the cytoplasm and nucleus (Supplementary Fig. S1A). This suggested that PAK1 was required for β-catenin stability within the normal mucosa. IHC staining of β-catenin in APCmin and APCmin/PAK1−/− adenomas also revealed that in the absence of PAK1, β-catenin levels were significantly reduced in both the cytoplasm and the nucleus (Fig. 2A; Supplementary Fig. S2). We also stained sections with a p-β-catenin (Ser 675) antibody and observed that p-β-catenin levels were reduced upon PAK1 deletion in APCmin mice (Fig. 2), and this effect was most profound in the nucleus (Supplementary Fig. S2).

Figure 2.

PAK1 deletion impairs Wnt/β-catenin signaling in APCmin adenomas. A, IHC staining and corresponding dot plots of PAK1, β-catenin, and p-β-catenin (Ser 675) in tumors of APCmin and APCmin/PAK1−/− mice. PAK1 was expressed throughout the tumor in APCmin mice and absent in APCmin/PAK1−/− mice. β-Catenin and p-β-catenin (Ser 675) expression were significantly reduced in adenomas of APCmin/PAK1−/− mice. IHC staining of two targets downstream of β-catenin, cyclin D1, and c-Myc shows PAK1 deletion did affect cyclin D1 expression levels but significantly reduced expression of c-Myc in APCmin polyps. IHC staining of p-AKT (Thr 308) demonstrates that p-AKT is reduced in tumors of APCmin/PAK1−/− mice. IHC data are at least (n = 5) mice per group. Independent samples t test. *, P < 0.05; **, P < 0.01; *, P < 0.001.

Figure 2.

PAK1 deletion impairs Wnt/β-catenin signaling in APCmin adenomas. A, IHC staining and corresponding dot plots of PAK1, β-catenin, and p-β-catenin (Ser 675) in tumors of APCmin and APCmin/PAK1−/− mice. PAK1 was expressed throughout the tumor in APCmin mice and absent in APCmin/PAK1−/− mice. β-Catenin and p-β-catenin (Ser 675) expression were significantly reduced in adenomas of APCmin/PAK1−/− mice. IHC staining of two targets downstream of β-catenin, cyclin D1, and c-Myc shows PAK1 deletion did affect cyclin D1 expression levels but significantly reduced expression of c-Myc in APCmin polyps. IHC staining of p-AKT (Thr 308) demonstrates that p-AKT is reduced in tumors of APCmin/PAK1−/− mice. IHC data are at least (n = 5) mice per group. Independent samples t test. *, P < 0.05; **, P < 0.01; *, P < 0.001.

Close modal

Important transcriptional targets of β-catenin include cyclin D1 and c-Myc. Cyclin D1 levels were not altered upon PAK1 deletion in APCmin adenomas, although total and nuclear c-Myc levels were significantly reduced in APCmin/PAK1−/− tumors (Fig. 2; Supplementary Fig. S2). Previous work demonstrated that 5-ASA reduces nuclear accumulation of β-catenin via inhibition of p-AKT (Thr-308; ref. 7). Considering that 5-ASA inhibits PAK1 and complete activation of AKT requires PAK1 (26), we also investigated whether PAK1 deletion impaired p-AKT (Thr-308) in APCmin adenomas. PAK1 deletion reduced total p-AKT levels and this effect was prominent within the nuclei of APCmin/PAK1−/− tumors (Fig. 2; Supplementary Fig. S2). These data suggest that PAK1 deletion reduces β-catenin, c-Myc, as well as the nuclear p-AKT.

The effect of PAK1 deletion on tumorigenesis in an AOM/DSS model of CAC

PAK1 is overexpressed in both IBD and CAC (17). However, it is unclear whether PAK1 overexpression promotes CAC and whether inhibition of PAK1 by 5-ASA is sufficient to curtail tumorigenesis in vivo. WT and PAK1−/− male and female mice received either a control or 5-ASA diet. After one intraperitoneal injection of AOM, mice received four cycles of DSS, which induced a chronic colitis that resulted in weight loss and bloody stool, followed by weight gain in the absence of DSS. Male and female mice were analyzed separately, as the PAK1−/− phenotype and 5-ASA effects were more pronounced in male mice. PAK1 deletion did not alter the severity of colitis (as measured by weight loss) in male (Fig. 3A) and female mice (Supplementary Fig. S3A). However, following the second cycle of DSS, 5-ASA–treated male WT mice weighed 26 g (24–28) and displayed a median difference of 3 g in comparison to untreated WT mice weighing 23 g (22–24; P = 0.004, ANOVA, LSD). This effect of 5-ASA was not present in PAK1−/− mice that weighed 24 g (23–25) and displayed a median difference of 1 g in comparison to 5-ASA–treated PAK1−/− mice 25g (24–26; P = 0.25, ANOVA, LSD; Fig. 3A) implicating that 5-ASA uses PAK1 to carry out certain protective effects. Such weight differences were not observed in female mice (Supplementary Fig. S3A).

Figure 3.

A–D, effect of PAK1 deletion on tumorigenesis in an AOM/DSS model. A, weight curves of male C57BL/6J WT and PAK1−/− mice with normal or 500 mg/kg 5-ASA chow throughout a 12-week AOM/DSS model. B, representative images of tumor size were taken during colonoscopy directly before euthanasia. Small tumors were <25%, medium <50%, and large >50% of the colon circumference. The control (Con) image was taken from an untreated mouse without AOM/DSS. C, boxplots are colonoscopy data demonstrating total tumor number, small, medium, and large tumors in all four groups. PAK1 deletion reduced total tumor number but did not alter tumor size. 5-ASA reduced total tumor number and size. D, microscopic analysis of total tumor number, dysplastic lesions, and carcinoma in situ. PAK1 deletion and 5-ASA reduced both the total tumor number and the number of dysplastic lesions. Neither PAK1 deletion nor 5-ASA altered the number of carcinoma in situ. All data are WT (n = 8), PAK1−/− (n = 13), WT + 5-ASA (n = 16), and PAK1−/− + 5-ASA (n = 13) mice. Statistical analyses were performed by ANOVA using LSD post hoc analysis. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Figure 3.

A–D, effect of PAK1 deletion on tumorigenesis in an AOM/DSS model. A, weight curves of male C57BL/6J WT and PAK1−/− mice with normal or 500 mg/kg 5-ASA chow throughout a 12-week AOM/DSS model. B, representative images of tumor size were taken during colonoscopy directly before euthanasia. Small tumors were <25%, medium <50%, and large >50% of the colon circumference. The control (Con) image was taken from an untreated mouse without AOM/DSS. C, boxplots are colonoscopy data demonstrating total tumor number, small, medium, and large tumors in all four groups. PAK1 deletion reduced total tumor number but did not alter tumor size. 5-ASA reduced total tumor number and size. D, microscopic analysis of total tumor number, dysplastic lesions, and carcinoma in situ. PAK1 deletion and 5-ASA reduced both the total tumor number and the number of dysplastic lesions. Neither PAK1 deletion nor 5-ASA altered the number of carcinoma in situ. All data are WT (n = 8), PAK1−/− (n = 13), WT + 5-ASA (n = 16), and PAK1−/− + 5-ASA (n = 13) mice. Statistical analyses were performed by ANOVA using LSD post hoc analysis. *, P < 0.05; **, P < 0.01; ***, P < 0.001.

Close modal

Histologic inflammation scoring revealed that WT and PAK1−/− mice presented with a moderate to severe colitis, such as a loss of two thirds of the crypts and severe infiltration of inflammatory cells in the lamina propria (Supplementary Fig. S3B). 5-ASA restored crypt architecture and reduced inflammation in the lamina propria in WT and PAK1−/− mice (Supplementary Fig. S3B and S3C).

Tumor multiplicity and size were evaluated via mouse colonoscopy 2 weeks after the fourth DSS cycle just before euthanization and by pathology (Fig. 3B). Colonoscopic scores revealed a median of 4 (2–10) tumors with no effect of PAK1 deletion on tumor multiplicity or size (for male and female subpopulations, see Fig. 3C; Supplementary Fig. S3D). Histologic analysis, however, identified far more lesions—a median of 14 (11–18)—per mouse (P < 0.0001 compared with colonoscopy; Fig. 3D; Supplementary Fig. S3E). Both PAK1 deletion and 5-ASA treatment reduced tumor multiplicity in male mice only (Fig. 3D; Supplementary Fig. S3E). 5-ASA treatment in PAK1−/− mice did not further impede total tumor number. Both PAK1 deletion and 5-ASA similarly reduced the number of dysplastic lesions but not the number of carcinoma in situ (Fig. 3D). These data suggest that (1) PAK1 deletion inhibits tumor initiation independent of intestinal inflammation, and (2) 5-ASA likely uses PAK1 to impede tumor initiation independent of its anti-inflammatory properties.

Inhibition of PAK1 impairs p-AKT, β-catenin signaling in chronic inflammation

PAK1 deletion and 5-ASA treatment similarly reduced tumor multiplicity and early dysplastic lesions. This suggested that PAK1 is required for tumor initiation; however, it was unclear whether 5-ASA actually inhibited PAK1 in AOM/DSS tumors. IHC detection of PAK1 in control and 5-ASA–treated WT mice confirmed that PAK1 was overexpressed in tumors but not in the corresponding normal mucosa (Fig. 4A; Supplementary Fig. S4A). Importantly, 5-ASA treatment reduced PAK1 expression in tumors (Fig. 4A).

Figure 4.

A and B, inhibition of PAK1 impairs AKT/β-catenin signaling in AOM/DSS tumorigenesis. A, IHC of PAK1 in control (Con) and 5-ASA–treated mice. PAK1 is overexpressed in tumors in comparison to normal mucosa, and 5-ASA treatment reduced PAK1 overexpression. The dot plot demonstrates the mean IRS generated from tumors in control (n = 11) and 5-ASA (n = 9)-treated WT mice. Statistical analyses were performed using the independent samples Mann–Whitney U test. *, P < 0.05. B, IHC images and IRS dot plots of β-catenin and p-β-catenin (Ser 675). PAK1 deletion and 5-ASA treatment reduced expression of both total and phospho β-catenin.

Figure 4.

A and B, inhibition of PAK1 impairs AKT/β-catenin signaling in AOM/DSS tumorigenesis. A, IHC of PAK1 in control (Con) and 5-ASA–treated mice. PAK1 is overexpressed in tumors in comparison to normal mucosa, and 5-ASA treatment reduced PAK1 overexpression. The dot plot demonstrates the mean IRS generated from tumors in control (n = 11) and 5-ASA (n = 9)-treated WT mice. Statistical analyses were performed using the independent samples Mann–Whitney U test. *, P < 0.05. B, IHC images and IRS dot plots of β-catenin and p-β-catenin (Ser 675). PAK1 deletion and 5-ASA treatment reduced expression of both total and phospho β-catenin.

Close modal

To elucidate pathways interfered by PAK1, we stained multiple 5-ASA targets (27), including p65, PPARγ, p-ERK, β-catenin, p-AKT, and p-mTOR (17) via IHC. Sequestration of p65 in the cytoplasm maintains NF-κB signaling in an inactive state, although its nuclear translocation is required for transcriptional activation. Staining of p65 revealed its expression was low, cytoplasmic, and largely absent throughout the majority of nuclei in tumors (Supplementary Fig. S4B). PAK1 deletion did not change p65 levels in the cytoplasm, nor in the nucleus. However, 5-ASA had a modest effect in reducing cytoplasmic p65 levels in WT (P = 0.281, ANOVA, LSD), but not PAK1−/− mice (Supplementary Fig. S4B). Next we asked whether the anti-inflammatory effect of 5-ASA required activation of the nuclear receptor PPARγ. 5-ASA was previously reported to increase the nuclear expression of PPARγ (3). Although PPARγ was expressed in tumors of WT mice, its nuclear expression was not increased upon PAK1 deletion or 5-ASA treatment (Supplementary Fig. S4B). We examined p-ERK1/2 levels to assess MAPK activation. p-ERK was highly expressed in both the cytoplasm and nucleus of WT tumors. PAK1 deletion but not 5-ASA treatment resulted in a modest reduction of p-ERK expression (Supplementary Fig. S4B).

Considering that PAK1 deletion reduced β-catenin expression in APCmin mice, we investigated the expression of total and p-β-catenin (Ser-675) in AOM/DSS tumors. Both PAK1 deletion and 5-ASA treatment reduced total and p-β-catenin (Ser-675) expression (Fig. 4B). Inhibition of total β-catenin levels by PAK1−/− or 5-ASA was pronounced throughout the cytoplasm, and p-β-catenin inhibition was more profound within the nucleus (Supplementary Fig. S4C). Importantly, PAK1 deletion and 5-ASA treatment together did not synergistically impede total or p-β-catenin expression. The downstream β-catenin target c-Myc was strongly downregulated upon PAK1 deletion and 5-ASA treatment (Fig. 5A; Supplementary Fig. S4D).

Figure 5.

A and B, IHC of c-Myc and p-AKT (Thr 308) in AOM/DSS tumors. A, PAK1 deletion and 5-ASA reduced nuclear expression of c-Myc. PAK1 deletion and 5-ASA reduced p-AKT (Thr 308) expression. The effect of 5-ASA on p-AKT (Thr 308) was blocked in PAK1−/− mice. Statistical analyses were performed by ANOVA using LSD post hoc analysis at least 4 mice per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001. B, PAK1 deletion impedes tumorigenesis but not tumor growth. A, schematic representation of PAK1 overexpression and activation of AKT–β-catenin signaling in an APCmin or an AOM/DSS adenoma. PAK1 overexpression increases the phosphorylation and nuclear localization of AKT and β-catenin. The nuclear expression of c-Myc is apparent throughout the tumor. B, representation of a dysplastic cell in which both 5-ASA treatment and PAK1 deletion reduce the phosphorylation and nuclear localization of AKT and β-catenin. As a consequence, c-Myc expression is reduced and tumorigenesis is impeded.

Figure 5.

A and B, IHC of c-Myc and p-AKT (Thr 308) in AOM/DSS tumors. A, PAK1 deletion and 5-ASA reduced nuclear expression of c-Myc. PAK1 deletion and 5-ASA reduced p-AKT (Thr 308) expression. The effect of 5-ASA on p-AKT (Thr 308) was blocked in PAK1−/− mice. Statistical analyses were performed by ANOVA using LSD post hoc analysis at least 4 mice per group. *, P < 0.05; **, P < 0.01; ***, P < 0.001. B, PAK1 deletion impedes tumorigenesis but not tumor growth. A, schematic representation of PAK1 overexpression and activation of AKT–β-catenin signaling in an APCmin or an AOM/DSS adenoma. PAK1 overexpression increases the phosphorylation and nuclear localization of AKT and β-catenin. The nuclear expression of c-Myc is apparent throughout the tumor. B, representation of a dysplastic cell in which both 5-ASA treatment and PAK1 deletion reduce the phosphorylation and nuclear localization of AKT and β-catenin. As a consequence, c-Myc expression is reduced and tumorigenesis is impeded.

Close modal

We also investigated whether PAK1 deletion impaired either p-AKT (Thr-308) in tumors of AOM/DSS mice. Both PAK1 deletion and 5-ASA treatment in WT mice reduced expression of p-AKT (308; Fig. 5A; Supplementary Fig. S4D). However, 5-ASA did not block p-AKT (308) expression in PAK1−/− mice indicating that 5-ASA uses PAK1 inhibition to block AKT. These data indicate that PAK1 may initiate tumorigenesis through activation of a p-AKT (Thr 308)–β-catenin cascade.

mTOR) signaling is downstream of p-AKT (308) and has been implicated in tumor growth and survival. Activation of mTOR implicated in tumorigenesis was also examined in these samples, as PAK1 contributes to mTOR signaling and 5-ASA inhibits mTOR (17, 28). IHC staining of p-mTOR revealed its activation in tumors of WT and PAK1−/− mice, although this effect was more profound in WT mice. Importantly, 5-ASA treatment reduced p-mTOR in WT mice and this effect was diminished upon PAK1 deletion (Supplementary Fig. S4E). These data suggest that 5-ASA uses PAK1 inhibition to impede mTOR signaling.

PAK1 is overexpressed in both sporadic and colitis-associated colorectal cancer (17, 19). Prolonged use of 5-ASA may impede colorectal tumorigenesis (2, 29), although the underlying mechanisms are unknown. We previously identified PAK1 as a 5-ASA target and here we investigated whether PAK1 deletion impaired tumorigenesis in mouse models of sporadic and CAC. We used APCmin/PAK1−/− mice to investigate the role of PAK1 upon loss of APC and found that PAK1 deletion impeded tumorigenesis without affecting tumor size. Furthermore, Wnt signaling was impaired via downregulation of β-catenin and c-Myc. We previously reported that PAK1 is overexpressed in IBD (17), and it is known that chronic inflammation in IBD increases the risk of CAC (30). We used an AOM/DSS mouse model in which WT and PAK1−/− mice received a 5-ASA–enriched diet and found that PAK1 deletion did not affect the severity of colitis but impaired tumor initiation without affecting tumor size. Mechanistically, PAK1 deletion diminished the effect of 5-ASA on reducing AKT–β-catenin signaling, resulting in downregulation of c-Myc, and reducing tumor initiation.

Mutation in the tumor suppressor APC is an initiating step in familial adenomatous polyposis and sporadic colorectal tumorigenesis (31) and results in aberrant β-catenin activation, which drives cell transformation within the crypt axis (32). The APCmin mouse model quickly recapitulates this process exhibiting a robust tumor load following loss of APC within 12 weeks (33). We previously observed that PAK1 was overexpressed in tumors of APCmin mice and that 5-ASA not only impeded tumor multiplicity but also reduced expression of PAK1, nuclear β-catenin, and its downstream target c-Myc. It was however unclear whether this effect of 5-ASA required PAK1 inhibition. Here, we bred APCmin and PAK1−/− mice to assess whether PAK1 deletion reduces tumorigenesis similar to 5-ASA. Indeed, PAK1 deletion reduced tumor multiplicity and the expression and phosphorylation of β-catenin and its target c-Myc. The transcription factor c-Myc regulates cell transformation and tumorigenesis and its deletion in APCmin mice reduced tumor multiplicity, which was also in line with our findings upon PAK1 deletion (34). This suggested that PAK1 drives tumorigenesis via β-catenin–c-Myc signaling.

In our model of CAC, PAK1 deletion impeded tumorigenesis specifically in male mice. Although we did not investigate this further, PAK1 mediates the effects of both testosterone and estrogen (35, 36). Therefore it is not surprising that PAK1 may play a gender-specific role in colorectal tumorigenesis. PAK1 deletion blocked tumor multiplicity and dysplastic lesions similar to the effect of 5-ASA in WT mice. Importantly, 5-ASA inhibited PAK1 expression in AOM/DSS tumors and did not further reduce tumor multiplicity or dysplastic lesions in PAK1−/− mice. This supported that 5-ASA uses PAK1 inhibition to impede tumor initiation, but not progression, as neither PAK1 deletion nor 5-ASA reduced tumor size or the number of in situ carcinoma.

5-ASA treatment, and not PAK1 deletion, reduced inflammation in this AOM/DSS model, implicating a PAK1-independent effect of 5-ASA on intestinal inflammation. He and colleagues reported that PAK1 knockdown reduced tumor growth using a xenograft model (20). We, however, did not observe this phenotype upon PAK1 deletion in either of our APCmin or AOM/DSS models. In the AOM/DSS model, the presence of chronic inflammation likely drives tumor growth even in the absence of PAK1. 5-ASA activation of PPARγ was required to reduce neoplasia in experimental models of colitis (3, 37). However, 5-ASA did not increase PPARγ expression in our AOM/DSS model, indicating that 5-ASA blocked inflammation and tumor size through an alternative pathway. Baan and colleagues reported that 5-ASA blocked cell proliferation though inhibition of mTOR signaling (28), and we recently demonstrated that 5-ASA inhibits an AKT-mTOR cascade (17), although an in vivo proof of concept was lacking. Here we found that 5-ASA blocked p-mTOR in AOM/DSS tumors, and this effect was reduced upon PAK1 deletion. These data led us to conclude that in addition to its anti-inflammatory effect, 5-ASA may reduce tumor size through inhibition of mTOR signaling.

Wnt/β-catenin signaling is a key driver of tumorigenesis, and PAK1regulates stability and transcriptional activity of β-catenin (13). Without inflammation, we observed that PAK1 deletion reduced total β-catenin expression throughout the crypt axis and in tumors of APCmin mice. However, PAK1 deletion was not sufficient to fully block its nuclear accumulation in chronic inflammation. It is likely that other PAKs, such as PAK4, which also phosphorylate β-catenin, may be triggered upon DSS, thereby bypassing the effect of PAK1 deletion and promoting tumor growth (38). Brown and colleagues demonstrated that 5-ASA blocks β-catenin via AKT inhibition in IL10−/− mice (7). In addition, we also observed that PAK1 is required for AKT–β-catenin activation in both APCmin and AOM/DSS tumors, and its deletion reduced c-Myc expression. Taken together, these data indicate that inhibition of PAK1 by 5-ASA blocks AKT–β-catenin signaling thereby reducing tumorigenesis.

Population-based studies suggest a chemopreventive role of nonsteroidal anti-inflammatory drugs (NSAID) in colorectal cancer; however, their efficacy and safety are not yet established. Anti-inflammatory effects of NSAIDs are through inhibition of COX1 and COX2 activity in the prostaglandin synthesis pathway. In contrast to COX1, COX2 is inducible by pro-inflammatory cytokines and oncogenic signaling. Whether PAK1 interferes with COX2-mediated tumorigenesis warrants further investigations. In a rat intestinal cell line IEC-18, angiotensin-II–dependent activation of COX2 promoter was shown to be mediated by a PAK1/MKK6/p38beta/CREB signaling cascade (39). Another study showed that in respiratory papilloma, COX2 expression was mediated by a Rac1/PAK/NF-κB pathway (ref. 40). A role of COX1 signaling was demonstrated in T-cell activation that was mediated by a Fyn/Vav/PAK1 cascade and NSAIDs inhibited this pathway, including PAK1 activation (41). Altogether, these data demonstrate that inhibition of PAK1 might modulate COX signaling. Although, efficacy of NSAIDs is not examined upon PAK1 deletion, we expect downregulation of COX activity in PAK1−/− mice. PAK1 has a role in regulating both immune functions and epithelial homeostasis; therefore, pharmacologic inhibition of PAK1 should be carefully considered to target its overexpression. PAK1−/− mice were reported with no distinct phenotype except for an impairment of the pathways, such as MAPK, AKT, and Wnt–β-catenin, which require PAK1 for full activation and also contribute to oncogenesis. PAK1 depletion however was associated with defects in the immune functions such as mast cell degranulation (42). In our study, germline deletion of PAK1 modulated tumorigenesis in both APCmin mice and in chemically induced AOM/DSS model; however, inflammation was not affected in the latter, indicating its role in the stromal compartment.

This is the first study to demonstrate that PAK1 modulates tumorigenesis in an APCmin model as well as in an AOM/DSS model of chronic inflammation. PAK1 deletion and 5-ASA treatment impeded tumorigenesis via impairment of a PAK1–AKT–β-catenin axis and the downstream target c-Myc (Figure 5B). Our results suggest that PAK1 may be a plausible target for chemoprevention, although further investigations are warranted to understand its specific role in epithelial and stromal compartments.

No potential conflicts of interest were disclosed.

Conception and design: K. Dammann, V. Khare, F. Harpain, C. Gasche

Development of methodology: K. Dammann

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): K. Dammann, F. Harpain

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): K. Dammann, V. Khare, F. Harpain, M. Lang, A. Kurtovic, I. Mesteri, R. Evstatiev, C. Gasche

Writing, review, and/or revision of the manuscript: K. Dammann, V. Khare, F. Harpain, R. Evstatiev, C. Gasche

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): F. Harpain, A. Kurtovic, C. Gasche

Study supervision: V. Khare, C. Gasche

Other (obtained funding): C. Gasche

The authors thank Nicolas Gasche for assistance in genotyping of the mice.

The financial support by the Federal Ministry of Economy, Family and Youth and the National Foundation for Research, Technology and Development is gratefully acknowledged. This study was supported in part by the Austrian Science Fund (P24121 to C. Gasche).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1.
Ullman
TA
,
Itzkowitz
SH
. 
Intestinal inflammation and cancer
.
Gastroenterology
2011
;
140
:
1807
16
.
2.
Velayos
FS
,
Terdiman
JP
,
Walsh
JM
. 
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies
.
Am J Gastroenterol
2005
;
100
:
1345
53
.
3.
Rousseaux
C
,
El-Jamal
N
,
Fumery
M
,
Dubuquoy
C
,
Romano
O
,
Chatelain
D
, et al
The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARgamma
.
Carcinogenesis
2013
;
34
:
2580
6
.
4.
Lyakhovich
A
,
Gasche
C
. 
Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine
.
Aliment Pharmacol Ther
2010
;
31
:
202
9
.
5.
Managlia
E
,
Katzman
RB
,
Brown
JB
,
Barrett
TA
. 
Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells
.
Inflamm Bowel Dis
2013
;
19
:
2051
60
.
6.
Luciani
MG
,
Campregher
C
,
Fortune
JM
,
Kunkel
TA
,
Gasche
C
. 
5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint
.
Gastroenterology
2007
;
132
:
221
35
.
7.
Brown
JB
,
Lee
G
,
Managlia
E
,
Grimm
GR
,
Dirisina
R
,
Goretsky
T
, et al
Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis
.
Gastroenterology
2010
;
138
:
595
605
,
e1
3
.
8.
Kim
H
,
Jeon
H
,
Kong
H
,
Yang
Y
,
Choi
B
,
Kim
YM
, et al
A molecular mechanism for the anti-inflammatory effect of taurine-conjugated 5-aminosalicylic acid in inflamed colon
.
Mol Pharmacol
2006
;
69
:
1405
12
.
9.
Khare
V
,
Lang
M
,
Dammann
K
,
Campregher
C
,
Lyakhovich
A
,
Gasche
C
. 
Modulation of N-glycosylation by mesalamine facilitates membranous E-cadherin expression in colon epithelial cells
.
Biochem Pharmacol
2014
;
87
:
312
20
.
10.
Khare
V
,
Lyakhovich
A
,
Dammann
K
,
Lang
M
,
Borgmann
M
,
Tichy
B
, et al
Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1
.
Biochem Pharmacol
2013
;
85
:
234
44
.
11.
Eswaran
J
,
Li
DQ
,
Shah
A
,
Kumar
R
. 
Molecular pathways: targeting p21-activated kinase 1 signaling in cancer–opportunities, challenges, and limitations
.
Clin Cancer Res
2012
;
18
:
3743
9
.
12.
Dammann
K
,
Khare
V
,
Gasche
C
. 
Tracing PAKs from GI inflammation to cancer
.
Gut
2014
;
63
:
1173
84
.
13.
Zhu
G
,
Wang
Y
,
Huang
B
,
Liang
J
,
Ding
Y
,
Xu
A
, et al
A Rac1/PAK1 cascade controls beta-catenin activation in colon cancer cells
.
Oncogene
2012
;
31
:
1001
12
.
14.
Park
MH
,
Kim
DJ
,
You
ST
,
Lee
CS
,
Kim
HK
,
Park
SM
, et al
Phosphorylation of beta-catenin at serine 663 regulates its transcriptional activity
.
Biochem Biophys Res Commun
2012
;
419
:
543
9
.
15.
Frost
JA
,
Swantek
JL
,
Stippec
S
,
Yin
MJ
,
Gaynor
R
,
Cobb
MH
. 
Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1
.
J Biol Chem
2000
;
275
:
19693
9
.
16.
Selyunin
AS
,
Alto
NM
. 
Activation of PAK by a bacterial type III effector EspG reveals alternative mechanisms of GTPase pathway regulation
.
Small GTPases
2011
;
2
:
217
21
.
17.
Dammann
K
,
Khare
V
,
Lang
M
,
Claudel
T
,
Harpain
F
,
Granofszky
N
, et al
PAK1 modulates a PPARgamma/NF-kappaB cascade in intestinal inflammation
.
Biochim Biophys Acta
2015
;
1853
:
2349
60
.
18.
Khare
V
,
Dammann
K
,
Asboth
M
,
Krnjic
A
,
Jambrich
M
,
Gasche
C
. 
Overexpression of PAK1 promotes cell survival in inflammatory bowel diseases and colitis-associated cancer
.
Inflamm Bowel Dis
2015
;
21
:
287
96
.
19.
Carter
JH
,
Douglass
LE
,
Deddens
JA
,
Colligan
BM
,
Bhatt
TR
,
Pemberton
JO
, et al
Pak-1 expression increases with progression of colorectal carcinomas to metastasis
.
Clin Cancer Res
2004
;
10
:
3448
56
.
20.
He
H
,
Huynh
N
,
Liu
KH
,
Malcontenti-Wilson
C
,
Zhu
J
,
Christophi
C
, et al
P-21 activated kinase 1 knockdown inhibits beta-catenin signalling and blocks colorectal cancer growth
.
Cancer Lett
2012
;
317
:
65
71
.
21.
Lang
M
,
Borgmann
M
,
Oberhuber
G
,
Evstatiev
R
,
Jimenez
K
,
Dammann
KW
, et al
Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling
.
Mol Cancer
2013
;
12
:
41
.
22.
McDaniel
AS
,
Allen
JD
,
Park
SJ
,
Jaffer
ZM
,
Michels
EG
,
Burgin
SJ
, et al
Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells
.
Blood
2008
;
112
:
4646
54
.
23.
Cooper
HS
,
Murthy
SN
,
Shah
RS
,
Sedergran
DJ
. 
Clinicopathologic study of dextran sulfate sodium experimental murine colitis
.
Lab Invest
1993
;
69
:
238
49
.
24.
Suzuki
R
,
Kohno
H
,
Sugie
S
,
Nakagama
H
,
Tanaka
T
. 
Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice
.
Carcinogenesis
2006
;
27
:
162
9
.
25.
Barker
N
,
Ridgway
RA
,
van Es
JH
,
van de Wetering
M
,
Begthel
H
,
van den Born
M
, et al
Crypt stem cells as the cells-of-origin of intestinal cancer
.
Nature
2009
;
457
:
608
11
.
26.
Higuchi
M
,
Onishi
K
,
Kikuchi
C
,
Gotoh
Y
. 
Scaffolding function of PAK in the PDK1-Akt pathway
.
Nat Cell Biol
2008
;
10
:
1356
64
.
27.
Campregher
C
,
Gasche
C
. 
Aminosalicylates
.
Best Pract Res Clin Gastroenterol
2011
;
25
:
535
46
.
28.
Baan
B
,
Dihal
AA
,
Hoff
E
,
Bos
CL
,
Voorneveld
PW
,
Koelink
PJ
, et al
5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer
.
Gut
2012
;
61
:
1708
15
.
29.
Rubin
DT
,
Cruz-Correa
MR
,
Gasche
C
,
Jass
JR
,
Lichtenstein
GR
,
Montgomery
EA
, et al
Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update
.
Inflamm Bowel Dis
2008
;
14
:
265
74
.
30.
Mantovani
A
,
Allavena
P
,
Sica
A
,
Balkwill
F
. 
Cancer-related inflammation
.
Nature
2008
;
454
:
436
44
.
31.
Najdi
R
,
Holcombe
RF
,
Waterman
ML
. 
Wnt signaling and colon carcinogenesis: beyond APC
.
J Carcinog
2011
;
10
:
5
.
32.
Schepers
A
,
Clevers
H
. 
Wnt signaling, stem cells, and cancer of the gastrointestinal tract
.
Cold Spring Harbor Perspect Biol
2012
;
4
:
a007989
.
33.
Su
LK
,
Kinzler
KW
,
Vogelstein
B
,
Preisinger
AC
,
Moser
AR
,
Luongo
C
, et al
Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene
.
Science
1992
;
256
:
668
70
.
34.
Ignatenko
NA
,
Holubec
H
,
Besselsen
DG
,
Blohm-Mangone
KA
,
Padilla-Torres
JL
,
Nagle
RB
, et al
Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse
.
Cancer Biol Ther
2006
;
5
:
1658
64
.
35.
Mazumdar
A
,
Kumar
R
. 
Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells
.
FEBS Lett
2003
;
535
:
6
10
.
36.
Gu
S
,
Kounenidakis
M
,
Schmidt
EM
,
Deshpande
D
,
Alkahtani
S
,
Alarifi
S
, et al
Rapid activation of FAK/mTOR/p70S6K/PAK1-signaling controls the early testosterone-induced actin reorganization in colon cancer cells
.
Cell Signal
2013
;
25
:
66
73
.
37.
Rousseaux
C
,
Lefebvre
B
,
Dubuquoy
L
,
Lefebvre
P
,
Romano
O
,
Auwerx
J
, et al
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma
.
J Exp Med
2005
;
201
:
1205
15
.
38.
Li
Y
,
Shao
Y
,
Tong
Y
,
Shen
T
,
Zhang
J
,
Li
Y
, et al
Nucleo-cytoplasmic shuttling of PAK4 modulates beta-catenin intracellular translocation and signaling
.
Biochim Biophys Acta
2012
;
1823
:
465
75
.
39.
Pham
H
,
Vincenti
R
,
Slice
LW
. 
COX-2 promoter activation by AT1R-Gq-PAK-p38beta signaling in intestinal epithelial cells
.
Biochim Biophys Acta
2008
;
1779
:
408
13
.
40.
Wu
R
,
Abramson
AL
,
Symons
MH
,
Steinberg
BM
. 
Pak1 and Pak2 are activated in recurrent respiratory papillomas, contributing to one pathway of Rac1-mediated COX-2 expression
.
Int J Cancer
2010
;
127
:
2230
7
.
41.
Paccani
SR
,
Patrussi
L
,
Ulivieri
C
,
Masferrer
JL
,
D'Elios
MM
,
Baldari
CT
. 
Nonsteroidal anti-inflammatory drugs inhibit a Fyn-dependent pathway coupled to Rac and stress kinase activation in TCR signaling
.
Blood
2005
;
105
:
2042
8
.
42.
Allen
JD
,
Jaffer
ZM
,
Park
SJ
,
Burgin
S
,
Hofmann
C
,
Sells
MA
, et al
p21-activated kinase regulates mast cell degranulation via effects on calcium mobilization and cytoskeletal dynamics
.
Blood
2009
;
113
:
2695
705
.